London, 1st March 2012. While the global generic pharmaceuticals market is expected to peak in 2012 owing to the patent expiry of several leading brands, regulations favouring generics and wider health insurance coverage by Governments and private bodies are expected to boost generic consumption.
The Global Generic Pharmaceuticals Market was estimated to be $ 123.85 billion in 2010, growing at a compound annual growth rate of 9.3 per cent. The top eight global markets, namely the United States, Germany, the United Kingdom, France, Japan, Canada, Italy and Spain account for 80 per cent of the total generic drug sales worldwide.
In Europe, developed generic markets such as Germany and The United Kingdom have very high rates of generic penetration, presenting very minimal growth rates. While emerging markets such as France, Italy and Spain have seen the extent of generics penetration increase steadily, pricing policies, incentive schemes and regulatory framework still pose a challenge to the market participants with regard to market access and profit margins.
“Focus of market participants is shifting towards les competitive yet commercially attractive segments such as difficult-to-produce drugs, specialty products and biosimilars,” explains Aiswariya Chidambaram, Research Analyst at Frost & Sullivan.
Looking at the key therapeutic areas, Central Nervous System (CNS) and Cardiovascular are the two largest markets segments, constituting nearly 38 per cent of the global generic pharmaceuticals market. However, therapeutic segments such as Rheumatology, oncology and respiratory are likely to witness significantly high growth rates, attracting the attention of market participants.
The top five generic pharmaceutical companies accounted for 39 per cent of the share in the global generic pharmaceuticals market in 2010.
Diversification of product portfolios, vertical integration across the value chain, and untapped potentials of the emerging markets are the main drivers of acquisitions growth of generic pharmaceutical companies. There will be a significant rise in the partnership deals of generic pharmaceutical companies in the future, since many generic companies rely upon M&A rather than organic growth to battle out the intense competition in the industry.
“Careful choice of product segments and appropriate time of entry into the market will enable the generic drug manufacturers to sustain amidst intense competition,” concludes Aiswariya Chidambaram.
Frost & Sullivan recently organised an on-demand web-conference entitled “Global Generic Pharmaceuticals Market – Brighter Times Ahead”. The web-conference summarises Ms Aiswariya Chidambaram’s findings, investigating the market opportunities in terms of the key therapeutic areas facing generic exposure and establishing an understanding of the current and future trends in the developed and emerging markets worldwide.
This web-conference will benefit biopharmaceuticals companies, pharmaceutical companies and technology providers in the biopharmaceutical industry.
To receive a presentation of the web-conference and a link to the recording, please send an email to Janique Morvan, Corporate Communications, at janique.morvan@frost.com, with your full contact details.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.
Contact:
Janique Morvan
Corporate Communications – Europe
P: +33 (0)1 42 81 20 37
M: +33 (0)6 79 22 41 42
E: janique.morvan@frost.com
http://www.frost.com
